Catalyst
Slingshot members are tracking this event:
FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi) in Acute Graft-Versus-Host Disease (GVHD)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| INCY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 23, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Gvhd, Acute Graft-versus-host Disease, Jakafi, Ruxolitinib, Acute Graft-versus-host Disease
